Last reviewed · How we verify
Bupivacaine 0.25%
At a glance
| Generic name | Bupivacaine 0.25% |
|---|---|
| Also known as | Bupivacaine, Sensorcaine®, CPPLAI, Plain marcaine, Marcaine |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Analgesia in Arthroscopic Shoulder Surgery (NA)
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
- mTLIP vs QIPB for Postoperative Analgesia in Lumbar Microdiscectomy Surgery (NA)
- Comparison of Femoral Nerve Block and Combined PENG Plus Femoral Nerve Block in Geriatric Hip Surgery (NA)
- SPSIPB vs CCB in Arthroscopic Shoulder Surgeries (NA)
- Parascapular Sub Iliocostalis Plane Block Versus Thoracic Paravertebral Plane Block for Traumatic Multiple Rib Fractures (NA)
- Comparison Between Tranversus Abdominis Plane (TAP) Block With Only Bupivacaine and TAP Block With Bupivacaine Plus Ketamine in Reducing Postoperative Pain After Total Abdominal Hystrectomy (PHASE1, PHASE2)
- Comparison of the Analgesic Efficacy of Chest Wall Blocks in Coronary Artery Bypass Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine 0.25% CI brief — competitive landscape report
- Bupivacaine 0.25% updates RSS · CI watch RSS
- Ain Shams University portfolio CI